COLLEGE STATION, Texas--(BUSINESS WIRE)--Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the GMP production of cell and gene therapies (CGTs), today announced the appointment of four experienced leaders in biotechnology and the life sciences to its board of advisors: Charlene Banard, Gerard Fleury, Evan Greger, and Carson Sublett..

德克萨斯州大学城-（商业线）-Matica Biotechnology，Inc。（Matica Bio），一家专门从事细胞和基因疗法（CGT）GMP生产的合同开发和制造组织（CDMO），今天宣布任命四位经验丰富的生物技术和生命科学领导者担任顾问委员会：Charlene Banard，Gerard Fleury，Evan Greger，和Carson Sublett。。

As the inaugural members of Matica Bio’s advisory board, these appointments will provide strategic oversight as the company executes the development, scale-up, and production of CGTs at its purpose-built GMP facility in Texas. Combined with Matica Bio’s bespoke approach to CGT manufacturing – enabled by a fully closed, single-use platform and industry-leading analytical capabilities – the incoming leadership of this newly established advisory board will further empower the company to meet the growing demand for CGT manufacturing expertise..

作为Matica Bio顾问委员会的就职成员，这些任命将提供战略监督，因为该公司在德克萨斯州的专用GMP设施中执行CGT的开发，放大和生产。结合Matica Bio定制的CGT制造方法（通过完全封闭的一次性平台和行业领先的分析能力），这个新成立的顾问委员会的新领导将进一步增强公司的能力，以满足对CGT制造专业知识日益增长的需求。。

“Matica Bio is thrilled to introduce the accomplished members of our newly formed board of advisors,” said Yun Jeong Song, M.D., president and chief executive officer of Matica Bio. “Through their extensive biomanufacturing experience and their unique expertise in diverse fields, the advisors will enhance the technical excellence of our in-house team.

Matica Bio的总裁兼首席执行官宋云杰说：“Matica Bio很高兴能够介绍我们新成立的顾问委员会的杰出成员。”通过他们丰富的生物制造经验和在各个领域的独特专业知识，顾问将提升我们内部团队的技术卓越性。

This synergy positions us to collaborate effectively with CGT developers, forging a path towards life-saving medicines and delivering greater client success.”.

这种协同作用使我们能够与CGT开发人员有效合作，为挽救生命的药物开辟道路，并为客户提供更大的成功。

Each of Matica Bio’s new board members will assume advisory roles in their respective areas of expertise to advance the company’s position within the CGT manufacturing industry:

Matica Bio的每个新董事会成员将在各自的专业领域担任顾问角色，以提升公司在CGT制造业中的地位：

Charlene Banard, quality and technical operations expert: Banard, who has led technical operations and driven quality excellence and lifecycle strategy for innovative technology platforms – including the first commercial allogeneic and autologous cell therapies – at companies including Novartis, Atara, Shire, Gilead and Cell Genesys will assume the role of quality and technical operations expert..

质量和技术运营专家Charlene Banard：Banard，在包括诺华，Atara，Shire，Gilead和Cell-Genesys将担任质量和技术运营专家的角色。。

Gerard Fleury, financial strategist: Fleury will apply his more than 30 years’ experience in CDMO focused corporate leadership – guiding companies through various business cycles including start-up, growth, hyper growth, optimization, and turnaround – as the board’s financial strategist.

金融战略家杰拉德·弗莱里（Gerard Fleury）：弗莱里（Fleury）将运用他30多年在以CDMO为重点的企业领导力方面的经验，指导公司通过各个业务周期，包括初创企业，成长企业，超增长企业，优化企业和周转企业，成为董事会的金融战略家。

Evan Greger, technical operations and product development expert: Greger, whose professional track record includes successful end-to-end biologic and CGT value generation, development, and commercialization at biotechnology companies including outsourced operations with Novartis, Juno Therapeutics, Cell Design Labs, and Amgen, will be the board’s technical operations and product development specialist..

Evan Greger，技术运营和产品开发专家：Greger，其专业记录包括生物技术公司成功的端到端生物和CGT价值生成，开发和商业化，包括与诺华，Juno Therapeutics，Cell Design Labs和Amgen的外包业务，将成为董事会的技术运营和产品开发专家。。

Carson Sublett, business operations advisor: Sublett has led business operations for one of the world's largest pharmaceutical companies, GalaxoSmithKline, and some of the industry’s leading CDMOs. He will guide Matica Bio’s business strategy as business operations advisor.

业务运营顾问Carson Sublett：Sublett领导了全球最大的制药公司之一GalaxoSmithKline和一些行业领先的CDMO的业务运营。他将指导Matica Bio的业务战略作为业务运营顾问。

The formation of Matica Bio’s board of advisors comes shortly after the hiring of Laura Parks as head of commercial operations and Heather N. Sugrue as vice president of business development. Earlier this year, Matica Bio launched MatiMax, a proprietary HEK293 cell line platform that includes both adherent and suspension cell lines of two different types, HEK293 and HEK293T, and can accelerate CGT development for biotech companies with enhanced speed and superior quality..

Matica Bio顾问委员会的成立是在雇用Laura Parks担任商业运营负责人和Heather N.Sugrue担任商业发展副总裁后不久。今年早些时候，Matica Bio推出了专有的HEK293细胞系平台MatiMax，该平台包括HEK293和HEK293T两种不同类型的贴壁细胞系和悬浮细胞系，可以加快生物技术公司的CGT开发速度和质量。。

About Matica Biotechnology, Inc.

关于Matica Biotechnology，Inc。

Matica Biotechnology, Inc. (Matica Bio) is a contract development and manufacturing organization (CDMO) specializing in fully integrated cell and gene therapy manufacturing. The industry-leading experts at our state-of-the-art facility in College Station, Texas, deliver breakthrough therapies rapidly and safely through innovative manufacturing solutions.

Matica Biotechnology，Inc。（Matica Bio）是一家合同开发和制造组织（CDMO），专门从事完全整合的细胞和基因治疗制造。我们位于德克萨斯州大学城的最先进设施的行业领先专家通过创新的制造解决方案快速安全地提供突破性治疗。

Advance your therapy from idea to patient with the experts at Matica Bio. Visit www.maticabio.com..

与Matica Bio的专家一起推进您的治疗方案。访问www.maticabio.com。。